| 1. |
|
|
| 2. |
|
|
| 3. |
- Carlsson, Jörgen, 1944-
(författare)
-
Developmental trends in targeted radionuclide therapy : Biological aspects
- 2008
-
Ingår i: Targeted Radionuclide Tumor Therapy. - New York : Springer. - 9781402086953 ; , s. 387-398
-
Bokkapitel (populärvet., debatt m.m.)abstract
- Targeted radionuclide therapy of hematopoietic malignancies in the clinical setting has been achieved and similar successes with solid tumors and cells disseminated from them are likely within reach. Recombinant technologies have led to the development of a number of new targeting agents and the evaluation of a number of putative new targets is currently in progress. These advances are currently under evaluation in the preclinical setting and are expected to transition into clinical trials before long. Many of these new agents exhibit both improved pharmacological properties and enhanced cellular retention, both of which may lead to substantial improvements over existing compounds. In addition, our knowledge of basic radiobiology and its impact on the different modes of cell death is rapidly expanding, leading to new understanding in the fundamental differences between hematopoietic and epithelial tumor cells. Such knowledge will likely have a significant influence on the development of future treatment modalities. Furthermore, the complex interactions between radiation induced intracellular signaling pathways and the crucial observation that low dose radiation (e.g. less than 15 Gy) is able to significantly affect the growth of disseminated solid tumors cells suggests to us that a new era in targeted radionuclide therapy may soon be here.
|
|
| 4. |
- Carlsson, Jörgen
(författare)
-
Effects of low dose-rate radiation on cellular survival
- 2008
-
Ingår i: Targeted Radionuclide Tumor Therapy. - New York : Springer. - 9781402086953 ; , s. 295-310
-
Bokkapitel (populärvet., debatt m.m.)abstract
- The experience of external radiotherapy can only to a limited extent be used to understand therapeutic effects of radionuclide therapy. A major difference is that the dose-rate at radionuclide therapy is at least two orders of magnitude lower. Part of this chapter deals with estimates of the necessary dose-rate and exposure time in combination in order to deliver therapeutic effects to tumour cells. It is proposed that combinations of about 0.1–0.2 Gy/h for several days or about 1 Gy/h for at least 1 day is necessary. Such dose-rates can be achieved with the help of cross fire radiation. Effects of radionuclide therapy in terms of apoptosis, cell-cycle blocks and hyperradiosensitivity are also discussed.
|
|
| 5. |
- Carlsson, Jörgen, 1944-
(författare)
-
EGFR-family expression and implications for targeted radionuclide therapy
- 2008
-
Ingår i: Targeted Radionuclide Therapy. - New York : Springer. - 9781402086953 ; , s. 25-58
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Summary High expression in the primary tumor of receptors in the EGFR-family is most often also accompanied by a similar high expression in corresponding metastases. This makes these receptors interesting as putative targets for targeted radionuclide therapy of metastases and disseminated tumor cells. The expression of all four family members, EGFR, HER2, HER3 and HER4 is reviewed in this chapter. Studies on breast, urinary bladder, colorectal, prostate, head and neck, esophageal and glioma tumors are described and possible strategies for targeted radionuclide therapy are discussed. Quantification of receptor expression and the possible influence of genomic stability on the expression are also discussed.
|
|
| 6. |
- Carlsson, Jörgen
(författare)
-
Introduction to radionuclide therapy
- 2008
-
Ingår i: Targeted Radionuclide Tumor Therapy. - New York : Springer. - 9781402086953 ; , s. 1-11
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- This introductory chapter is written for those who are new to the field and desire a short overview of the present status of clinical and preclinical radionuclide therapy. In particular, this chapter provides an overview of the radiophysical concepts and key aspects of dosimetry and treatment planning that are beyond the scope of this book’s focus on biological aspects of radionuclide therapy. Finally, a discussion on the choice of radionuclides and the availability of radiopharmaceuticals is provided.
|
|
| 7. |
- Carlsson, Thomas, et al.
(författare)
-
Farliga ämnen
- 2006
-
Ingår i: Farliga och miljöstörande material i hus. - Stockholm : Formas. - 9789154059799 ; , s. 49-53/-61-62
-
Bokkapitel (populärvet., debatt m.m.)
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
